Compare AbbVie Inc (ABBV) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? AbbVie Inc trades at $248.5 (market cap $441.94B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $42.63. The key difference: AbbVie Inc pays a 2.77% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none, and AbbVie Inc is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | GPTY | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $263.58 | $50.52 |
52-Week Low | $197.38 | $34.73 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
GPTY trades at $42.64, up 0.94% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on AI and tech equities, using options strategies to generate weekly dividends, with recent payouts ranging from $0.28 to $0.37. Support and resistance levels are clustered around $41-$43, indicating tight trading ranges.
Outlook is supported by AI theme momentum and income generation, but risks include semiconductor concentration and NAV erosion from options strategies. Investor sentiment is mixed, with some analysts highlighting yield sustainability concerns versus exposure benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
